nct_id: NCT06645678
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2024-10-17'
study_start_date: '2024-11-26'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Dexamethasone'
  - drug_name: 'Drug: Elranatamab'
  - drug_name: 'Drug: Mezigdomide'
long_title: Phase I/II Study of Mezigdomide and Elranatamab for Relapsed/refractory
  Multiple Myeloma Patients
last_updated: '2024-12-24'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: NA
principal_investigator_institution: Seoul National University Hospital
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 75
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- '* Subjects must satisfy the following criteria to be enrolled in the study:'
- "* Subject is \u2265 19 years of age at the time of signing the informed consent\
  \ form (ICF)."
- "\u2461 Subject must understand and voluntarily sign an ICF prior to any study-related\
  \ assessments/procedures being conducted."
- '* Subject is willing and able to adhere to the study visit schedule and other protocol
  requirements.'
- "\u2463 Subject has documented diagnosis of MM and measurable disease, defined as\
  \ any of the following: A. M-protein \u2265 0.5 g/dL by serum protein electrophoresis\
  \ (sPEP) or B. M-protein \u2265 200 mg/24-hour urine collection by urine protein\
  \ electrophoresis (uPEP) or C. For subjects without measurable disease in sPEP or\
  \ uPEP: serum free light chain (sFLC) levels \\&gt; 100 mg/L (10 mg/dL) involved\
  \ light chain and an abnormal kappa/lambda FLC ratio."
- '\*Patients with measurable disease and extramedullary disease will be allowed to
  participate if there is a measurable extramedullary lesion. These patients require
  PET-CT follow-up for response evaluation. Those with extramedullary disease (EMD)
  only will not be allowed to participate: i.e, Patients with plasmacytoma as the
  only measurable disease are not eligible. For the definition of EMD, refer to Section
  8.1.3.'
- "\u2464 Subject has received 2 or more prior lines of antimyeloma therapy. (Note:\
  \ One line can contain several phases \\[e.g., induction, (with or without) hematopoietic\
  \ stem cell transplant, (with or without) consolidation, and/or (with or without)\
  \ maintenance therapy)."
- "\u2465 Subject must have received at least one proteasome inhibitor and lenalidomide."
- "\u2466 Subject achieved minimal response or better to at least 1 prior antimyeloma\
  \ therapy."
- '* Subject must have documented disease progression during or after their last antimyeloma
  regimen.'
- "\u2468 Subject has an Eastern Cooperative Oncology Group (ECOG) performance status\
  \ score of 0, 1 or 2."
- "\u2469 Individual of childbearing potential (IOCBP) must: A. Have two negative\
  \ pregnancy tests as verified by the Investigator prior to starting study treatment.\
  \ She must agree to ongoing pregnancy testing during the course of the study, and\
  \ after the end of study treatment. This applies even if the subject practices true\
  \ abstinence\\* from heterosexual contact."
- 'B. Either commit to true abstinence\* from heterosexual contact (which must be
  reviewed on a monthly basis and source documented) or agree to use, and be able
  to comply with, 2 forms of contraception: one highly effective, and one additional
  effective (barrier) measure of contraception without interruption 28 days prior
  to starting study treatment, during the study treatment (including dose interruptions),
  and for at least 28 days after the last dose of mezigdomide or 150 days after the
  last dose of elranatamab, whichever is longer.'
- 'Note: A IOCBP (Individual of childbearing potential): an individual who: 1) has
  achieved menarche (first menstrual cycle) at some point; 2) has not undergone a
  hysterectomy (the surgical removal of the uterus) or bilateral salpingectomy (the
  surgical removal of the fallopian tubes) or oophorectomy (the surgical removal of
  both ovaries) or 3) has not been naturally postmenopausal (without an alternative
  medical cause eg, amenorrhea following cancer therapy does not rule out childbearing
  potential) for at least 12 consecutive months (ie, has had menses at any time during
  the preceding 12 consecutive months).'
- "\u246A Male subjects must: A. Practice true abstinence\\* (which must be reviewed\
  \ on a monthly basis) or agree to use a condom during sexual contact with a pregnant\
  \ individual or an individual of childbearing potential while participating in the\
  \ study, during dose interruptions and for at least 28 days after the last dose\
  \ of mezigdomide whichever is longer, even if he has undergone a successful vasectomy."
- '* True abstinence is acceptable when this is in line with the preferred and usual
  lifestyle of the subject. \[Periodic abstinence (e.g., calendar, ovulation, post-ovulation
  methods) and withdrawal are not acceptable methods of contraception\].'
- '* Male subjects must agree to refrain from donating sperm while on study treatment,
  during dose interruptions and for at least 28 days following last dose of mezigdomide,'
- '* Females must agree to refrain from donating eggs while on study treatment and
  for at least 28 days after last dose of mezigdomide.'
- '* Subjects must agree to refrain from donating blood while on study treatment,
  during dose interruptions and for at least 28 days following the last dose of mezigdomide.'
- '* Subjects must agree to refrain from receiving live vaccines while on study treatment,
  during dose interruptions and for at least 90 days following the last dose of the
  study treatment.'
- 'Exclude - Exclusion Criteria: The presence of any of the following will exclude
  a subject from enrollment:'
- Exclude - * 1 Subject who has had prior treatment with mezigdomide. 2 Patients with
  gastrointestinal disease or surgery (eg, gastric bypass surgery) that may significantly
  alter the absorption of mezigdomide and/or other oral study intervention.
- Exclude - 3 Subject who has had prior treatment with anti-BCMA agents (including
  CAR T-cell therapy, bispecifics and antibodies).
- Exclude - 4 Subject who has had any investigational agents within 28 days or 5 half-lives
  (whichever is shorter) of initiating study treatment.
- Exclude - A. Participation in another interventional clinical trial concurrent with
  this study is not permitted, except for those who have completed treatment with
  the prior investigational agent(s) and are currently in Long-term Follow up.
- Exclude - 5 Subject has received any of the following. A. Plasmapheresis within
  the last 28 days of initiating study treatment B. Major surgery (as defined by the
  Investigator) within 28 days of initiating study treatment.
- Exclude - C. Radiation therapy, other than local palliative therapy, for myeloma
  associated bone lesions within 14 days of initiating study treatment.
- Exclude - D. Use of any systemic antimyeloma drug therapy within 14 days of initiating
  study treatment.
- Exclude - E. Use of potassium competitive acid blockers (eg. tegoprazan, vonoprazan)
  within 7 days of initiating study treatment.
- Exclude - 6 Subject has previously received allogeneic stem cell transplantation
  within a year during prior therapy or received autologous stem cell transplantation
  within 12 weeks of initiating study treatment. Patients who received allogeneic
  stem cell transplantation should not have evidence of active GVHD.
- Exclude - 7 Subject has plasma cell leukemia defined by IMWG definition for primary
  plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy,
  organomegaly, endocrinopathy, monoclonal protein, and skin changes) or clinically
  significant light-chain amyloidosis.
- Exclude - 8 Subject with known central nervous system (CNS) involvement with myeloma.
  9 Subject has any significant medical condition, including active or uncontrolled
  infection, presence of laboratory abnormality, or psychiatric illness that places
  the subject at an unacceptable risk for treatment-related complications, if he/she
  were to participate in the study.
- Exclude - 10 Coronavirus disease 2019 (COVID-19) within 7 days for mild or asymptomatic
  infections or 14 days for moderate/severe infections prior to initiating study intervention.
  A longer duration may be needed based on the investigator's clinical judgment.
- Exclude - i) Acute symptoms must have resolved and there are no sequelae that would
  place the participant at a higher risk of receiving study intervention, based on
  investigator Assessment. No repeat/follow-up COVID-19 testing is required
- Exclude - 11 Subject has any condition that confounds the ability to interpret data
  from the study.
- "Exclude - 12 Subject has any of the following laboratory abnormalities: A. Absolute\
  \ neutrophil count (ANC) \\< 1,000/\xB5L. It is not permissible to administer GCSF\
  \ to achieve minimum ANC levels within 7 days prior to screening complete blood\
  \ count (CBC) (or within 14 days prior for pegfilgrastim).\\* B. Platelet count:\
  \ \\< 75,000/\xB5L for subjects in whom \\< 50% of bone marrow nucleated cells are\
  \ plasma cells; or a platelet count \\< 50,000/\xB5L for subjects in whom \u2265\
  \ 50% of bone marrow nucleated cells are plasma cells (transfusions are not permitted\
  \ within 7 days prior to screening CBC).\\* C. Hemoglobin \\< 8 g/dL (\\< 4.9 mmol/L).\\\
  *"
- Exclude - \* Participants who do not meet criteria for hematologic function because
  of MM-related cytopenias (e.g. due to extensive marrow involvement by MM) may receive
  transfusions and be screened after 1 week of transfusion.
- Exclude - D. Estimated glomerular filtration rate (eGFR) \< 30 mL/min or requiring
  dialysis. eGFR will be calculated using the Modification of Diet in Renal Disease
  (MDRD) formula.
- "Exclude - E. Corrected serum calcium \\> 13.5 mg/dL (\\> 3.4 mmol/L) F. Serum aspartate\
  \ aminotransferase (AST) or alanine aminotransferase (ALT) \\> 2.5 \xD7 upper limit\
  \ of normal (ULN) G. Serum total bilirubin \\> 1.5 \xD7 ULN, or for participants\
  \ with documented Gilbert's syndrome \\> 3.0 mg/dL 13 Subject has peripheral neuropathy\
  \ \u2265 Grade 2 14 Subject with gastrointestinal disease or surgery (e.g., gastric\
  \ bypass surgery) that may significantly alter the absorption of mezigdomide and/or\
  \ other oral study treatment."
- "Exclude - A. Subject has a prior history of malignancies other than MM, except\
  \ if the participant has been free of the disease for \u2265 3 years. Patients with\
  \ CIS treated with curative intent are not excluded if less than 3 years. Exceptions\
  \ would include basal cell and squamous cell cancer of the skin treated with curative\
  \ intent."
- 'Exclude - 15 Subject has received immunosuppressive medication within the last
  14 days of initiating study treatment. The following are exceptions to this criterion:
  a. Intranasal, inhaled, topical or local corticosteroid injections (e.g., intra-articular
  injection). b. Systemic corticosteroids at doses that do not exceed 10 mg/day of
  prednisone or the equivalent. c. Steroids as premedication for hypersensitivity
  reactions (e.g., computed tomography \[CT\] scan premedication).'
- Exclude - 16 Administration of strong CYP3A modulators; administration of proton-pump
  inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole)
  within 2 weeks of starting study treatment.
- 'Exclude - 17 Impaired cardiovascular function or clinically significant cardiovascular
  diseases, defined as any of the following within 6 months prior to enrollment: A.
  Acute myocardial infarction or acute coronary syndromes (eg, unstable angina, coronary
  artery bypass graft, coronary angioplasty or stenting, symptomatic pericardial effusion);
  B. Clinically significant cardiac arrhythmias (eg, uncontrolled atrial fibrillation
  or uncontrolled paroxysmal supraventricular tachycardia); C. Thromboembolic or cerebrovascular
  events (eg, transient ischemic attack, cerebrovascular accident, deep vein thrombosis
  \[unless associated with a central venous access complication\] or pulmonary embolism);
  D. Prolonged QT syndrome (or QTcF \> 470 msec at screening); E. LVEF \<40% as determined
  by a MUGA scan or echocardiography. 18 Subject has uncontrolled hypertension or
  uncontrolled diabetes within 14 days prior to enrollment.'
- Exclude - 19 Subject who has had a live vaccine within 3 months of start of study
  therapy.
- Exclude - 20 Subject is unable or unwilling to undergo protocol required thromboembolism
  or antiviral prophylaxis.
- 'Exclude - 21 Subject is positive for human immunodeficiency virus (HIV), chronic
  or active hepatitis B, active hepatitis A, or active hepatitis C: A. Known positive
  HIV status. B. Seropositive for hepatitis B (defined by a positive test for hepatitis
  B surface antigen \[HBsAg\] either acute or chronic hepatitis). Subjects with resolved
  infection (i.e., subjects who are HBsAg negative but positive for antibodies to
  hepatitis B core antigen \[anti-HBcAb\] and/or antibodies to hepatitis B surface
  antigen \[anti-HBsAb\]) must be screened using real-time polymerase chain reaction
  (PCR) measurement of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels.
  Those who are PCR positive will be excluded.'
- 'Exclude - EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination
  (anti-HBs positivity as the only serologic marker) AND a known history of prior
  HBV vaccination, do not need to be tested for HBV DNA by PCR.'
- 'Exclude - EXCEPTION: Subjects with positive anti-HBcAb but negative HBsAg and negative
  anti-HBsAb profiles are eligible if HBV DNA PCR is negative.'
- Exclude - C. Known to be seropositive for hepatitis C virus (HCV); anti-HCV antibody
  positive and HCV- ribonucleic acid (RNA) quantitation positive.
- "Exclude - 22 Subject has a history of anaphylaxis or hypersensitivity to thalidomide,\
  \ lenalidomide, pomalidomide (including \u2265 Grade 3 rash during prior IMiD therapy),\
  \ or dexamethasone or the excipients contained in the formulations, or subject has\
  \ any contraindications per local PI."
- Exclude - 23 Ongoing Grade 3 or higher peripheral sensory or motor neuropathy, history
  of Guillan-Barre syndrome (GBS) or GBS variants, or history of any Grade \> 3 peripheral
  motor polyneuropathy.
- Exclude - 24 Subject is an individual who is pregnant, nursing or breastfeeding,
  or who intends to become pregnant during participation in the study.
short_title: Mezigdomide and Elranatamab for Relapsed And/or Refractory Multiple Myeloma
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: YOUNGIL KOH
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: The goal of this clinical trial is to find out how well a combination of
  two medicines (mezigdomide and elranatamab) works in treating patients with refractory/relapsed
  multiple myeloma.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Treatment arm
      arm_internal_id: 0
      arm_description: 'Participants will receive elranatamab, mezigdomide and dexamethasone.


        Part 1 (safety cohort): approximately 12 participants to select the optimal
        RP2D and to assess the safety, tolerability, and preliminary efficacy. Every
        cycle consists of 28 days.


        Part 2 (expansion cohort): approximately 63 participants will be enrolled.
        The primary objective of Part 2 is to determine the overall response rate
        per IMWG criteria at 24 months after enrollment.'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Elranatamab'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Mezigdomide'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Dexamethasone'
        level_internal_id: 2
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=19'
        disease_status:
        - Recurrent
        - Refractory
        oncotree_primary_diagnosis: Lymphoid Neoplasm
